Integrin Antagonists 27 |
| Katalog-Nr.GC32967 |
Integrin Antagonists 27 ist ein niedermolekularer Integrin-αvβ3-Antagonist mit einer BindungsaffinitÄt von 18 nM als neuartiges Antikrebsmittel.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 593274-97-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Integrin Antagonists 27 is a small molecule integrin αvβ3 antagonist with binding affinity of 18 nM, as s novel anticancer agent. Target: Integrinin vitro: Integrin Antagonists 27 is treated with a panel of cancer cell-lines (breast cancer cell line MDA-MB-435, breast cancer cell lines MCF-7, mouse fibroblast NIH3T3, ovarian cancer cell line HEY, lung cancer cell line NCI-H1975) with all IC50 of >20 uM.
[1]. Dayam R, et al. Discovery of small molecule integrin alphavbeta3 antagonists as novel anticancer agents. J Med Chem. 2006 Jul 27;49(15):4526-4534.
Average Rating: 5 (Based on Reviews and 8 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *